Neurorehabilitation News

Stressors in life can contribute to poor functional, cognitive and neuropsychiatric outcomes up to a year after being hospitalized with COVID-19, researchers reported in the Journal of Neurological Science.

Medical device company WISE Srl announced the FDA granted clearance for its Cortical Strip, a single-use device intended to be used on the brain surface for intraoperative neurophysiological monitoring.

NeuroPace Inc. announced that the first patient with Lennox-Gastaut Syndrome was treated in its investigational device exemption feasibility study, which will evaluate the company’s neuromodulation technology.

Clinical-stage biopharmaceutical company Clene Inc. announced proof-of-concept evidence of potential neuroprotective effects of CNM-Au8, an oral therapeutic for patients with stable relapsing-remitting MS.

Biotechnology company Cajal Neuroscience announced its launch with $96 million Series A financing with plans to combine human genetics, functional genomics and advanced microscopy to expand drug discovery for neurodegenerative diseases.

A team of researchers at the University of Miami Miller School of Medicine have developed an online platform of metrics designed to assess a patient’s risk for developing Alzheimer’s disease and other neurological issues.

The Pershing Square Foundation announced the launch of the Maximizing Innovation in Neuroscience Discover prize to establish a community of multidisciplinary investigators who can improve understanding of the brain and cognition.

Treatment with inebilizumab was associated with reduction in aquaporin-4 antibody titers and B cells for those with neuromyelitis optica spectrum disorder, according to an expert at ECTRIMS 2022.

For adults in the U.K., preexisting neuropsychiatric conditions and having a prescription for a related treatment carried a significantly increased risk of severe outcomes from COVID-19 and other severe acute respiratory infections.

Lusaris Therapeutics announced its launch with $60 million in Series A financing to advance LSR-1019, a sublingual formulation of 5-MeO-DMT for patients with treatment-resistant depression and other severe neuropsychiatric disorders.